Open Access
Issue
Published:
03 April 2023
Fatal ventricular arrhythmias after osimertinib treatment for lung adenocarcinoma: a case report
)
Download citation
663
Views
78
Downloads
3
Crossref
2
WoS
2
Scopus
1
CSCD
menu
Fatal ventricular arrhythmias after osimertinib treatment for lung adenocarcinoma: a case report
)
References(30)
Ramalingam SS, Yang JC, Lee CK, et al. Osimertinib As First-Line Treatment of EGFR Mutation-Positive Advanced Non-Small-Cell Lung Cancer. J Clin Oncol 2018; 36: 841−849.
Yang JC, Ahn MJ, Kim DW, et al. Osimertinib in pretreated T790M-positive advanced non-small-cell lung cancer: AURA study phase II extension component. J Clin Oncol 2017; 35: 1288−1296.
John T, Akamatsu H, Delmonte A, et al. EGFR mutation analysis for prospective patient selection in AURA3 phase III trial of osimertinib versus platinum-pemetrexed in patients with EGFR T790M-positive advanced non-small-cell lung cancer. Lung Cancer 2018; 126: 133−138.
Anand K, Ensor J, Trachtenberg B, Bernicker EH. Osimertinib-Induced Cardiotoxicity: A Retrospective Review of the FDA Adverse Events Reporting System (FAERS). JACC Cardio Oncol 2019; 1: 172−178.
Yu J, Fang T, Yun C, et al. Antibody-drug conjugates targeting the human epidermal growth factor receptor family in cancers. Front Mol Biosci 2022; 9: 847835.
Lindeman NI, Cagle PT, Aisner DL, et al. Updated molecular testing guideline for the selection of lung cancer patients for treatment with targeted tyrosine kinase inhibitors: guideline from the college of american pathologists, the international association for the study of lung cancer, and the association for molecular pathology. J Mol Diagn 2018; 20: 129−159.
Ma H, Tian X, Zeng XT, et al. The efficacy of erlotinib versus conventional chemotherapy for advanced nonsmall-cell lung cancer: a PRISMA-compliant systematic review with meta-regression and meta-analysis. Medicine (Baltimore) 2016; 95: e2495.
Soria JC, Ohe Y, Vansteenkiste J, et al. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N Engl J Med 2018; 378: 113−125.
Ramalingam SS, Vansteenkiste J, Planchard D, et al. Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC. N Engl J Med 2020; 382: 41−50.
Kunimasa K, Kamada R, Oka T, et al. Cardiac adverse events in EGFR-mutated non-small cell lung cancer treated with osimertinib. JACC Cardio Oncol 2020; 2: 1−10.
Ewer MS, Tekumalla SH, Walding A, Atuah KN. Cardiac safety of osimertinib: a review of data. J Clin Oncol 2021; 39: 328−337.
Mok TS, Wu YL, Ahn MJ, et al. Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer. N Engl J Med 2017; 376: 629−640.
Matsuura C, Kato T, Koyama K. Successful management of refractory torsades de pointes due to drug-induced long QT syndrome guided by point-of-care monitoring of ionized magnesium. Cureus 2021; 13: e13939.
Ikebe S, Amiya R, Minami S, et al. Osimertinib-induced cardiac failure with QT prolongation and torsade de pointes in a patient with advanced pulmonary adenocarcinoma. Int Cancer Conf J 2021; 10: 68−71.
Bian S, Tang X, Lei W. A case of torsades de pointes induced by the third-generation EGFR-TKI, osimertinib combined with moxifloxacin. BMC Pulm Med 2020; 20: 181.
Kaira K, Ogiwara Y, Naruse I. Occurrence of ventricular fibrillation in a patient with lung cancer receiving osimertinib. J Thorac Oncol 2020; 15: e54−e55.
Zhang Y, Wang X, Pan Y, et al. Overdrive pacing in the acute management of osimertinib-induced ventricular arrhythmias: A case report and literature review. Front Cardiovasc Med 2022; 9: 934214.
Li S, Xu Z, Guo M, et al. Drug-induced QT Prolongation Atlas (DIQTA) for enhancing cardiotoxicity management. Drug Discov Today 2022; 27: 831−837.
Garcia-Quiroz J, Gonzalez-Gonzalez ME, Diaz L, et al. Astemizole, an Inhibitor of Ether-a-Go-Go-1 potassium channel, increases the activity of the tyrosine kinase inhibitor gefitinib in breast cancer cells. Rev Invest Clin 2019; 71: 186−194.
Teisseyre A, Palko-Labuz A, Sroda-Pomianek K, Michalak K. Voltage-gated potassium channel Kv1.3 as a target in therapy of cancer. Front Oncol 2019; 9: 933.
Aissaoui D, Mlayah-Bellalouna S, Jebali J, et al. Functional role of Kv1.1 and Kv1. 3 channels in the neoplastic progression steps of three cancer cell lines, elucidated by scorpion peptides. Int J Biol Macromol 2018; 111: 1146−1155.
Jin T, Hu B, Chen S, et al. An in vitro assay of hERG K (+) channel potency for a new EGFR inhibitor FHND004. Front Pharmacol 2018; 9: 577.
Chakraborty AD, Gonano LA, Munro ML, et al. Activation of RyR2 by class I kinase inhibitors. Br J Pharmacol 2019; 176: 773−786.
Liu S, Li S, Hai J, et al. Targeting HER2 aberrations in non-small cell lung cancer with osimertinib. Clin Cancer Res 2018; 24: 2594−2604.
Das D, Xie L, Wang J, et al. In vivo efficacy studies of novel quinazoline derivatives as irreversible dual EGFR/HER2 inhibitors, in lung cancer xenografts (NCI-H1975) mice models. Bioorg Chem 2020; 99: 103790.
Nicolazzi MA, Carnicelli A, Fuorlo M, et al. Anthracycline and trastuzumab-induced cardiotoxicity in breast cancer. Eur Rev Med Pharmacol Sci 2018; 22: 2175−2185.
Dempsey N, Rosenthal A, Dabas N, et al. Trastuzumab-induced cardiotoxicity: a review of clinical risk factors, pharmacologic prevention, and cardiotoxicity of other HER2-directed therapies. Breast Cancer Res Treat 2021; 188: 21−36.
Chihara Y, Takeda T, Goto Y, et al. A phase II trial on osimertinib as a first-line treatment for EGFR mutation-positive advanced NSCLC in elderly patients: The SPIRAL-0 Study. Oncologist 2022; 27: e834−e903.
FEEDBACK 
TOP